Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00298883
Status:
COMPLETED
Last Update Posted:
2012-07-25
First Post:
2006-03-01
Brief Title:
Desensitization of Renal Transplant Candidates
Sponsor:
University of Florida
Organization:
University of Florida
Study Overview
Official Title:
Desensitization of Renal Transplant Candidates
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Trial of the use of Myfortic to reduce anti-HLA alloantibody in patients waiting for renal transplantation
Detailed Description:
Pre-formed HLA antibodies prevent renal transplantation because of the risk of hyperacute rejection We propose a prospective study evaluating the efficacy of Enteric Coated Mycophenolate Sodium Myfortic in decreasing the titers of anti-HLA alloantibodies in patients awaiting kidney transplantation Myfortic is an immunosuppressant that inhibits the proliferation of B and T cells by blocking the enzyme inosine monophosphate dehydrogenase We will attempt to determine whether a 6-week course of Myfortic adequately decreases the antibody reactivity to a level compatible with transplantation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None